#Israel #Jerusalem #Biopharmaceutical #Scinai #CDMO

Scinai Immunotherapeutics Expands CDMO Business

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical leader focused on immunotherapeutics, recently made headlines with its latest move to expand its Contract Development and Manufacturing Organization (CDMO) services. This development comes in the form of a $5.1 million definitive agreement with a Nasdaq-listed biopharmaceutical company based in the U.S., indicating a significant step forward for Scinai in securing its market position.

Major Commitment to Innovation and Growth

The newly signed agreement marks an expansion of an existing customer engagement, emphasizing Scinai's commitment to providing high-quality, tailored services within the biopharmaceutical sector. The terms of this arrangement include approximately $5.1 million in committed base service fees. These services are anticipated to contribute positively to Scinai's revenue streams throughout 2026 and 2027, with additional stability services extending beyond this period.

In recent developments, the total of committed customer orders across Scinai's operations has skyrocketed to roughly $7.6 million, reflecting an impressive increase of 300% from $1.9 million at the close of 2025. Notably, this increase positions the company well above the $3.1 million reported just a few months prior.

Future Prospects in Manufacturing and Revenue Generation

Amir Reichman, Scinai's CEO, articulated the importance of this agreement, stating that it significantly enhances their contracted CDMO business and aligns with their goal of delivering bespoke services to international clients. The engagement sets a solid foundation for a clinical manufacturing program that is slated to initiate in January 2027. Such initiatives underscore Scinai's commitment to translating agreements into revenue and enhanced operational performance.

Scinai's growth trajectory is not just limited to immediate financial gains. The agreement encapsulates a broad array of integrated chemistry, manufacturing, and controls (CMC) services tailored to support an investigational oncology product. It comprises process and analytical development, manufacturing readiness, and IND-enabling activities, ensuring Scinai's offerings remain competitive and cutting-edge.

Additional Opportunities and Potential Expansion

Looking ahead, Scinai’s agreement holds the prospect of additional clinical manufacturing endeavors that could yield an uncommitted service-fee value of approximately $5.85 million from late 2027 to mid-2028. This indicates a flourishing relationship with potential commercial manufacturing opportunities, contingent upon regulatory advancements and the successful exchange of agreements.

Scinai is also prepared to address project-related costs separately, including procurement and handling charges, reinforcing their structured approach to customer service while ensuring additional revenue generation through these operations.

About Scinai Immunotherapeutics

Founded with a vision to revolutionize immunotherapy solutions, Scinai operates through its wholly-owned subsidiary, Scinai Biopharma Services Ltd., located in Jerusalem and Yavne, Israel. By providing a spectrum of development and manufacturing services, Scinai appeals to both the biotech and pharmaceutical sectors, hence solidifying its role as a leader in the growing field of biotechnology. The company also actively collaborates on its NanoAb platform with esteemed institutions like the Max Planck Society and the University Medical Center Göttingen.

As the biopharmaceutical landscape evolves, Scinai remains committed to driving innovation and delivering exceptional service, positioning itself strategically for future growth and success within the sector. The upcoming years promise to be pivotal for Scinai as it leverages its expanded CDMO capabilities to meet the growing demands of the market while continuing its commitment to high-quality pharmaceutical development.